<HTML>
<HEAD>
<BASE target="_top">
<TITLE>United States Patent: 6084120</TITLE></HEAD>
<!-BUF1=6084120
BUF7=2000
BUF8=75834
BUF9=/1/
BUF51=6
-->
<BODY bgcolor="#FFFFFF">
<A name="top"></A>
<CENTER>
<IMG src="/netaicon/PTO/patfthdr.gif" alt="[US Patent & Trademark Office, Patent Full Text and Image Database]">
<BR>
<TABLE>
<TR><TD align="center">
<A href="/netahtml/PTO/index.html"><IMG src="/netaicon/PTO/home.gif" alt="[Home]" border="0" valign="middle"></A>
<A href="/netahtml/PTO/search-bool.html"><IMG src="/netaicon/PTO/boolean.gif" alt="[Boolean Search]" border="0" valign="middle"></A>
<A href="/netahtml/PTO/search-adv.htm"><IMG border="0" src="/netaicon/PTO/manual.gif" ALT="[Manual Search]" valign="middle"></A>
<A href="/netahtml/PTO/srchnum.htm"><IMG src="/netaicon/PTO/number.gif" alt="[Number Search]" border="0" valign="middle"></A>
<A href="/netahtml/PTO/help/help.htm"><IMG border="0" valign="middle" src="/netaicon/PTO/help.gif" ALT="[Help]"></A>
</TD></TR>
<TR><TD align="center">
   <A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=35&p=1&f=S&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&Query=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/hitlist.gif border=0 ALT=[HIT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=35&p=2&f=S&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&Query=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextlist.gif border=0 ALT=[NEXT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=34&p=1&f=G&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&OS=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/prevdoc.gif border=0 ALT=[PREV_DOC]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=36&p=1&f=G&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&OS=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextdoc.gif border=0 ALT=[NEXT_DOC]></A>

<A href="#bottom"><IMG src="/netaicon/PTO/bottom.gif" alt="[Bottom]" valign="middle" border="0"></A>
</TD></TR>
   <TR><TD align="center">
   <A href="https://certifiedcopycenter.uspto.gov/other/patft/view.html?backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D35%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(chloroquine.TI.%252BOR%252Bchloroquine.ABTX.)%26OS%3D%252B((ttl%2Fchloroquine%252Bor%252Babst%2Fchloroquine))&backLabel1=Back%20to%20Document%3A%206084120"><IMG border="0" src="/netaicon/PTO/cart.gif" border="0" valign="middle" alt="[View Shopp
ing Cart]"></A>
   <A href="https://certifiedcopycenter.uspto.gov/other/patft/order.html?docNumber=6084120&backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D35%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(chloroquine.TI.%252BOR%252Bchloroquine.ABTX.)%26OS%3D%252B((ttl%2Fchloroquine%252Bor%252Babst%2Fchloroquine))&backLabel1=Back%20to%20Document%3A%206084120">
   <IMG border="0" src="/netaicon/PTO/order.gif" valign="middle" alt="[Add to Shopping Cart]"></A>
   </TD></TR>
   <TR><TD align="center">
   <a href=http://pdfpiw.uspto.gov/.piw?Docid=06084120&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D35%2526p%3D1%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526S1%3D(chloroquine.TI.%252BOR%252Bchloroquine.ABTX.)%2526OS%3D%252B((ttl%2Fchloroquine%252Bor%252Babst%2Fchloroquine))%2526RS%3D(TTL%2Fchloroquine%252BOR%252BABST%2Fchloroquine)&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page><img src="/netaicon/PTO/image.gif" alt="[Image]" border="0" valign="middle"></A>

   </TD></TR>
</TABLE>
</CENTER>
<TABLE width="100%">
<TR><TD align="left" width="50%">&nbsp;</TD>
<TD align="right" valign="bottom" width="50%"><FONT size="-1">( <STRONG>35</STRONG></FONT> <FONT size=-2>of</FONT> <STRONG><FONT size=-1>58</STRONG> )</FONT></TD></TR></TABLE>
<HR>
   <TABLE width="100%">
   <TR>	<TD align="left" width="50%"><b>United States Patent </b></TD>
   <TD align="right" width="50%"><b>6,084,120</b></TD>
   </TR>
     <TR><TD align="left" width="50%"><b>
         Alzeer
, &nbsp; et al.</b>
     </TD>
     <TD align="right" width="50%"> <b>
     July 4, 2000
</b></TD>
     </TR>
     </TABLE>
       <TABLE width="100%">
       <TR>
       <TD align="center" width="100%"><FONT size="-2"><b>**Please see images for: </b>
         <FONT size="-2"><b>( Certificate of Correction ) </b>
       <FONT size="-2"><b> **</b>
       </TD>
       </TR>
       </TABLE>
       <HR>
       <FONT size="+1"> .beta.-Alkoxyacrylates against malaria
</FONT><BR>
       <BR><CENTER><b>Abstract</b></CENTER>
       <p>The present invention relates to compounds having the formulae
     ##STR1##
     wherein R, R.sup.1, R.sup.6, R.sup.7, Rn.sup.8, X, and Z are defined
     herein, which are useful in the treatment or prophylaxis of malaria. The
     compounds of the present invention are especially useful in the treatment
     or prophylaxis of <B><I>chloroquine</I></B>-sensitive and <B><I>chloroquine</I></B>-resistant malaria.
</p>
       <HR>
<TABLE width="100%"> <TR> <TH scope="row" valign="top" align="left" width="10%">Inventors:</TH> <TD align="left" width="90%">
 <B>Alzeer; Jawad</B> (Basel, <B>CH</B>)<B>, Chollet; Jacques</B> (Basel, <B>CH</B>)<B>, Hubschwerlen; Christian</B> (Durmenach, <B>FR</B>)<B>, Matile; Hugues</B> (Basel, <B>CH</B>)<B>, Ridley; Robert George</B> (Birsfelden, <B>CH</B>) </TD> </TR>
<TR> <TH scope="row" valign="top" align="left" width="10%">Assignee:</TH>
<TD align="left" width="90%">

<B>Hoffmann-La Roche Inc.</B>
 (Nutley, 
NJ)
<BR>

</TD>
</TR>
       <TR><TH scope="row" valign="top" align="left" width="10%" nowrap>Family ID:
       </TD><TD align="left" width="90%">
       <b>8227034
</b></TD></TR>
       <TR><TH scope="row" valign="top" align="left" width="10%" nowrap>Appl. No.:
       </TH><TD align="left" width="90%">
       <b> 09/102,463</b></TD></TR>
       <TR><TH scope="row" valign="top" align="left" width="10%">Filed:
       </TH><TD align="left" width="90%">
       <b>June 22, 1998</b></TD></TR>
     </TABLE>
     <HR>
<CENTER><b>Foreign Application Priority Data</b></CENTER> <hr align="center" width="30%"> <TABLE width="100%"> <TR><TH scope="col"></TH><TD></TD><TD></TD><TH scope="col"></TH><TD></TD></TR> <TR><TD align="center">
Jul 9, 1997
[EP]</TD><TD></TD><TD></TD><TD align='left'>
97111607</TD></TR><TR><TD align=center>

</TD>
</TR> </TABLE>
<p> <TABLE width="100%"> <TR><TD valign="top" align="left" width="30%"><b>Current U.S. Class:</b></TD> <TD valign="top" align="right" width="70%"><b>558/414</b>; 544/183; 560/125; 548/187; 549/499; 560/127; 562/507; 562/510; 549/79; 549/58; 546/173; 548/572; 546/342 </TD></TR> 
       <TR><TD valign="top" align="left" width="30%"><b>Current CPC Class: </b></TD>
       <TD valign="top" align="right" width="70%">A61K 31/352&nbsp(20130101); A61K 31/36&nbsp(20130101); C07D 333/28&nbsp(20130101); A61K 31/427&nbsp(20130101); A61K 31/4709&nbsp(20130101); A61P 33/06&nbsp(20180101); C07D 213/55&nbsp(20130101); C07D 277/30&nbsp(20130101); A61K 31/40&nbsp(20130101); A61K 31/4436&nbsp(20130101); A61K 31/426&nbsp(20130101); A61K 31/506&nbsp(20130101); C07D 333/24&nbsp(20130101); A61K 31/216&nbsp(20130101); A61K 31/381&nbsp(20130101); A61K 31/425&nbsp(20130101); A61K 31/53&nbsp(20130101); A61K 31/423&nbsp(20130101); A61K 31/498&nbsp(20130101); A61K 31/433&nbsp(20130101); A61K 31/4409&nbsp(20130101); C07D 333/60&nbsp(20130101); A61K 31/4402&nbsp(20130101); A61K 31/4406&nbsp(20130101); A61K 31/42&nbsp(20130101); A61K 31/343&nbsp(20130101); A61K 31/437&nbsp(20130101); A61K 31/341&nbsp(20130101); C07C 69/734&nbsp(20130101); A61K 31/47&nbsp(20130101); C07D 307/54&nbsp(20130101); C07C 251/48&nbsp(20130101); C07D 215/14&nbsp(20130101); Y02A 50/411&nbsp(20180101)</TD></TR>
         <TR><TD valign="top" align="left" width="30%"><b>Current International Class: </b></TD>
         <TD valign="top" align="right" width="70%">A61K 31/53&nbsp(20060101); A61K 31/506&nbsp(20060101); A61K 31/216&nbsp(20060101); A61K 31/47&nbsp(20060101); A61K 31/21&nbsp(20060101); A61K 31/498&nbsp(20060101); A61K 31/4709&nbsp(20060101); C07C 251/00&nbsp(20060101); C07C 251/48&nbsp(20060101); C07D 333/60&nbsp(20060101); C07D 333/24&nbsp(20060101); C07C 69/734&nbsp(20060101); A61K 31/40&nbsp(20060101); A61K 31/437&nbsp(20060101); A61K 31/357&nbsp(20060101); A61K 31/423&nbsp(20060101); C07D 213/55&nbsp(20060101); A61K 31/341&nbsp(20060101); A61K 31/352&nbsp(20060101); C07D 215/14&nbsp(20060101); A61K 31/36&nbsp(20060101); C07D 213/00&nbsp(20060101); A61K 31/4427&nbsp(20060101); A61K 31/4436&nbsp(20060101); A61K 31/4402&nbsp(20060101); A61K 31/426&nbsp(20060101); A61K 31/343&nbsp(20060101); C07D 307/54&nbsp(20060101); A61K 31/381&nbsp(20060101); A61K 31/433&nbsp(20060101); A61K 31/425&nbsp(20060101); C07D 307/00&nbsp(20060101); A61K 31/4406&nbsp(20060101); A61K 31/4409&nbsp(20060101); A61K 31/4353&nbsp(20060101); A61K 31/42&nbsp(20060101); A61K 31/427&nbsp(20060101); C07D 333/00&nbsp(20060101); C07D 277/00&nbsp(20060101); C07C 69/00&nbsp(20060101); C07D 277/30&nbsp(20060101); C07D 333/28&nbsp(20060101); C07D 215/00&nbsp(20060101); C07C 255/50&nbsp(); C07C 229/34&nbsp(); C07D 253/08&nbsp(); C07D 333/72&nbsp()</TD></TR>
       <TR><TD valign="top" align="left" width="30%"><b>Field of Search: </b></TD>
       <TD align="right" valign="top" width="70%">
       












 ;560/125,127 ;562/510,507 ;544/183 ;558/414 ;546/173,342 ;548/187,572 ;549/58,79,499
       </TD></TR>
     </TABLE>
<HR><CENTER><b>References Cited  <A href="/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/6084120">[Referenced By]</A></b></CENTER>       <HR>
       <CENTER><b>U.S. Patent Documents</b></CENTER>
<TABLE width="100%"> <TR><TH scope="col" width="33%"></TH> <TH scope="col" width="33%"></TH> <TH scope="col" width="34%"></TH></TR> <TR> <TD align="left">
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F4723034">4723034</a></TD><TD align =left>
February 1988</TD><TD align=left>
Schirmer et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5118710">5118710</a></TD><TD align =left>
June 1992</TD><TD align=left>
Wingert et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5334607">5334607</a></TD><TD align =left>
August 1994</TD><TD align=left>
Sauter et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5356931">5356931</a></TD><TD align =left>
October 1994</TD><TD align=left>
Kirstgen et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5376677">5376677</a></TD><TD align =left>
December 1994</TD><TD align=left>
Trah</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5389619">5389619</a></TD><TD align =left>
February 1995</TD><TD align=left>
Doetzer et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5409954">5409954</a></TD><TD align =left>
April 1995</TD><TD align=left>
Kirstgen et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5563168">5563168</a></TD><TD align =left>
October 1996</TD><TD align=left>
Brand et al.</TD></TR><TR><TD align=left>

</TD>
</TR> </TABLE>
       <CENTER><b>Foreign Patent Documents</b></CENTER>
<TABLE width="100%"> <TR><TD></TD><TH scope="col"></TH> <TD></TD><TH scope="col"></TH> <TD></TD><TH scope="col"></TH></TR> <TR> <TD align="left">
</TD><TD align=left>178 826</TD><TD></TD><TD align=left>
Oct 1985</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>254 426</TD><TD></TD><TD align=left>
Jun 1987</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>278 595</TD><TD></TD><TD align=left>
Jan 1988</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>299 694</TD><TD></TD><TD align=left>
Jul 1988</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>370 629</TD><TD></TD><TD align=left>
Oct 1989</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>379 098</TD><TD></TD><TD align=left>
Jan 1990</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>433 233</TD><TD></TD><TD align=left>
Dec 1990</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>460 575</TD><TD></TD><TD align=left>
Jun 1991</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>463 488</TD><TD></TD><TD align=left>
Jun 1991</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>474 042</TD><TD></TD><TD align=left>
Aug 1991</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>475 158</TD><TD></TD><TD align=left>
Aug 1991</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>0 515 901 A1</TD><TD></TD><TD align=left>
May 1992</TD><TD></TD><TD align=left>
EP</TD></TR><TR><TD align=left>
</TD><TD align=left>2 670 782</TD><TD></TD><TD align=left>
Jun 1992</TD><TD></TD><TD align=left>
FR</TD></TR><TR><TD align=left>
</TD><TD align=left>35 19 280 A1</TD><TD></TD><TD align=left>
Dec 1986</TD><TD></TD><TD align=left>
DE</TD></TR><TR><TD align=left>
</TD><TD align=left>90 07493</TD><TD></TD><TD align=left>
Jul 1990</TD><TD></TD><TD align=left>
WO</TD></TR><TR><TD align=left>

</TD>
</TR> </TABLE>
<TABLE width="90%"> <BR> <CENTER><b>Other References</b></CENTER> <TR><TD><align="left"><BR>Derwent Abstract: FR 2670781A.
.<BR>Derwent Abstract: WO 9007493A.
.<BR>Derwent Abstract: EP 460575A.. </TD></TR> </TABLE> <BR>
       <i>Primary Examiner:</i>  McKane; Joseph
<BR>
       <i>Assistant Examiner:</i>  Solola; Taofiq A.
<BR>
       <i>Attorney, Agent or Firm:</i> <coma><coma><coma>Johnston; George W.
Rocha-Tramaloni; Patricia S.
Ebel; Eileen M.
<BR>
         <HR>
<CENTER><b><i>Claims</b></i></CENTER> <HR> <BR><BR>What is claimed is: <BR><BR>1.  A compound of formula ##STR298## wherein R.sup.1 is lower alkyl;
<BR><BR>X is N or CH;
<BR><BR>R.sup.4 is hydrogen or lower alkyl;  and
<BR><BR>A.sup.5 is phenyl which is unsubstituted or substituted by one or more substituents, selected from lower alkyl, lower alkoxy, NO.sub.2, halogen, cyano or CF.sub.3 ;  pyridin-2-yl;  pyridin-4-yl;  quinolin-2-yl;  quinolin-3-yl;  naphthyl; 
pyrrol-2-yl, which is unsubstituted or substituted by lower alkyl;  furan-2-yl, furan-3-yl;  thien-2-yl;  thien-3-yl, , which is unsubstituted or substituted by halogen or lower alkyl;  thiazol-2-yl, which is unsubstituted or substituted by C.sub.6
H.sub.4 Cl;  thiazol-4-yl, which is unsubstituted or substituted by phenyl;  benzo[b]thiophen-2-yl, which is unsubstituted or substituted by halogen;  or benzo[b]thiophen-3-yl;
<BR><BR>as well as the stereoisomers and racemates thereof, and their pharmaceutically acceptable salts.
<BR><BR>2.  The compound of claim 1, wherein R.sup.1 is methyl.
<BR><BR>3.  The compound of claim 2, wherein R.sup.4 is hydrogen.
<BR><BR>4.  The compound of claim 3, wherein X is CH.
<BR><BR>5.  The compound of claim 4, wherein A.sup.5 is phenyl which is substituted by one or more substitutents selected from lower alkyl, lower alkoxy, NO.sub.2, halogen, cyano, or CF.sub.3.
<BR><BR>6.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2-Chloro-3,4-dimethoxyphenyl)-buta-1,3-dienyl]-phenyl ]-3-methoxy-acrylic acid methyl ester.
<BR><BR>7.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2-bromo-4,5-dimethoxy-phenyl)-buta-1,3-dienyl]-phenyl ]-3-methoxy-acrylic acid methyl ester.
<BR><BR>8.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2-cyano-phenyl)-buta-1,3-dienyl]-3-methoxy-acrylic acid methyl ester.
<BR><BR>9.  The compound of claim 5, (E)-3-methoxy-2-[2-[(1E,3E)-4-(3-methoxy-2-nitro-phenyl)-buta-1,3-dienyl]-
<BR><BR>phenyl]-acrylic acid methyl ester.
<BR><BR>10.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(4-fluoro-2-trifluoromethyl-phenyl)-buta-1,3-dienyl]-p henyl]-3-methoxy-acrylic acid methyl ester.
<BR><BR>11.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(4-tert-butyl-phenyl)-buta-1,3-dienyl]-phenyl]-3-metho xy-acrylic acid methyl ester.
<BR><BR>12.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2-chloro-4-fluoro-phenyl)-buta-1,3-dienyl]-phenyl]-3- methoxy-acrylic acid methyl ester.
<BR><BR>13.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2,4-diuoro-phenyl)-buta-1,3-dienyl]-phenyl]-3-methoxy -acrylic acid methyl ester.
<BR><BR>14.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2-chloro-4-methyl-phenyl)-buta-1,3-dienyl]-phenyl]-3- methoxy-acrylic acid methyl ester.
<BR><BR>15.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2,4-dimethyl-phenyl)buta-1,3-dienyl]-phenyl]-3-methox y-acrylic acid methyl ester.
<BR><BR>16.  The compound of claim 5, (E)-2-[2-[(1E,3E)-4-(2-fluoro-4-trifluoromethyl-phenyl-buta- 1,3-dienyl]-phenyl]-3-methoxy-acrylic acid methyl ester.
<BR><BR>17.  The compound of claim 5, Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(alpha,alpha,alpha-trifluoro-tolyl)-1,3-buta dienyl]phenyl]acrylate.
<BR><BR>18.  The compound of claim 5, (E)- or (Z)-2-[2-[4-(2,4-bis-trifluoromethyl-phenyl)-buta-1,3-dienyl]phenyl]-3-met hoxy-acrylic acid methyl ester.
<BR><BR>19.  The compound of claim 5, Methyl(E)-2-[o-[(all-E)-4-(o-bromophenyl)-1,3-butadienyl]phenyl]-3-methoxy acrylate.
<BR><BR>20.  The compound of claim 3, wherein X is N.
<BR><BR>21.  The compound of claim 20, (Z)- or (E)-Methoxyimino-[2-[(1E,2E)-4-(2-truoromethylphenyl)-buta-1,3-dienyl]-phe nyl]-acetic acid methyl ester. <HR> <CENTER><b><i>Description</b></i></CENTER> <HR> <BR><BR>The invention relates to compounds of
the formulae ##STR2## wherein
<BR><BR>R.sup.1 is lower alkyl
<BR><BR>X is N or CH ##STR3## wherein
<BR><BR>Y is S or O and
<BR><BR>A.sup.1 is phenyl which is unsubstituted or substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, CF.sub.3, NO.sub.2, NH.sub.2, phenoxy or CF.sub.3 -phenoxy; naphthyl; isothiazol-3-yl; thiazol-2-yl which is
unsubstituted or substituted by lower alkoxy-alkoxyalkyl, lower alkyl, lower alkoxycarbonyl or lower acetoxyalkyl; thiadiazol-2-yl which is unsubstituted or substituted by lower alkylthio, lower alkinylthio, cycloalkyl-alkylthio, CF.sub.3 or -NHC.sub.6
H.sub.4 CF.sub.3 ; quinoxalin-2-yl which is unsubstituted or substituted by halogen or lower alkyl; benzoxazol-2-yl; benzotriazine which is unsubstituted or substituted by an oxo-group; and quinolin-2-yl; ##STR4## wherein
<BR><BR>R.sup.2 is hydrogen, lower alkoxycarbonyl, CF.sub.3, lower alkyl, cycloalkyl, lower alkoxyalkyl, lower alkylthioalkyl or lower alkoxy; and
<BR><BR>A.sup.2 is phenyl which is unsubstituted or substituted by one or more substituents selected from lower alkyl, CF.sub.3, halogen, lower alkylthio, lower alkoxy or NO.sub.2 ; --C(O)C.sub.6 H.sub.5 ; --C(CH.sub.3).dbd.CH--C.sub.6 H.sub.4 -lower
alkyl; --CH.dbd.CH--C.sub.6 H.sub.5 ; pyridin-2-yl; pyridin-3-yl; pyridin-4-yl; thiazol-5-yl which is unsubstituted or substituted by lower alkyl; thien-3-yl which is unsubstituted or substituted by lower alkyl; thien-2-yl which is unsubstituted or
substituted by halogen; quinolin-2-yl; naphthyl; benzo[b]thiophen-2-yl, which is unsubstituted or substituted by lower alkyl or halogen; or benzo[b]furan-2-yl; ##STR5## wherein
<BR><BR>W is S, O, NH or CH.sub.2 ;
<BR><BR>R.sup.3 is hydrogen or lower alkyl; and
<BR><BR>A.sub.3 is 5-acetoxy-6-acetoxymethyl-5,6-dihydro-2H-pyran or phenyl which is unsubstituted or substituted by one or more substituents selected from halogen, CF.sub.3 or lower alkyl; ##STR6## wherein
<BR><BR>A.sup.4 is phenyl which is unsubstituted or substituted by one or more substituents selected from NO.sub.2, lower alkoxy, halogen, CF.sub.3, phenyloxy, styryl-phenyl or (2-CF.sub.3 - or Cl-phenyl)-furan-2-yl; benzo[1,3]dioxol-5-yl which is
unsubstituted or substituted by halogen; isoxazol-4-yl which is unsubstituted or substituted by phenyl or lower alkoxyalkoxy; quinolin-3-yl; pyridin-2-yl; pyridin-3-yl; pyridin-4-yl; furyl; thien-2-yl; thien-3-yl; --C.tbd.C--C(CH.sub.3).sub.3 ;
--C.tbd.C--C.sub.6 H.sub.5 ; indolizin-2-yl which is unsubstituted or substituted by lower alkyl; benzofuran-2-yl; benzopyran-3-yl or dihydrobenzo[b]thiophen-5-yl; ##STR7## wherein
<BR><BR>R.sup.4 is hydrogen or lower alkyl; and
<BR><BR>A.sup.5 is phenyl substituted by one or more substituents selected from lower alkyl, lower alkoxy, NO.sub.2, halogen, cyano or CF.sub.3 ; pyridin-2-yl; pyridin-4-yl; quinolin-2-yl; quinolin-3-yl; naphthyl; pyrrol-2-yl substituted by lower alkyl;
furan-2-yl; furan-3-yl; thien-2-yl; thien-3-yl which is unsubstituted or substituted by halogen and lower alkyl; thiazol-2-yl which is unsubstituted or substituted by C.sub.6 H.sub.4 Cl; thiazol-4-yl which is unsubstituted or substituted by phenyl;
benzo[b]thiophen-2-yl which is unsubstituted or substituted by halogen; or benzo[b]thiophen-3-yl; ##STR8## wherein
<BR><BR>A.sup.6 is phenyl which is unsubstituted or substituted by CF.sub.3 ; ##STR9## wherein
<BR><BR>A.sup.7 is phenyl which is unsubstituted or substituted by CF.sub.3 ;
<BR><BR>or --(CH.sub.2).sub.n -A.sup.8 Ia8
<BR><BR>wherein
<BR><BR>n is 4and
<BR><BR>A.sup.8 is phenyl which is unsubstituted or substituted by one or more substituents selected from CF.sub.3, halogen or --CH.dbd.N--OCH.sub.2 -CO--OCH.sub.3 ; naphthyl; or pyridin-4-yl; ##STR10## wherein
<BR><BR>A.sup.9 is phenyl which is unsubstituted or substituted by CF.sub.3 ;
<BR><BR>and wherein in formula IB each of
<BR><BR>R.sup.6, R.sup.7
<BR><BR>and R.sup.8 are hydrogen, lower alkyl or lower alkoxy and
<BR><BR>Z is hydrogen; lower alkoxy; lower alkyl; or halogen ##STR11## wherein
<BR><BR>V is O, --N(CH.sub.3)--, --S-- and
<BR><BR>B.sup.1 is phenyl which is unsubstituted or substituted by halogen or alkyl; quinolin-8-yl; pyrimidin-2-yl; --CH(CH.sub.3)--C.sub.6 H.sub.5 ; or --CH.sub.2 --C.sub.6 H.sub.5 ; ##STR12## wherein
<BR><BR>m is 0 or 1; and
<BR><BR>B.sup.2 is phenyl which is unsubstituted or substituted by halogen, lower alkyl or CF.sub.3 ; or benzo[b]thiophen-5-yl; ##STR13## wherein
<BR><BR>B.sup.3 is phenyl which is unsubstituted or substituted by CF.sub.3 ; ##STR14## wherein
<BR><BR>R.sup.5 is hydrogen, lower alkyl or lower alkoxyalkyl and
<BR><BR>B.sup.4 is phenyl which is unsubstituted or substituted by CF.sub.3 ; pyridin-2-yl; or thiazolin-5-yl which is unsubstituted or substituted by lower alkyl; ##STR15## wherein
<BR><BR>B.sup.5 is phenyl; --C.tbd.C--C(CH.sub.3).sub.3 ; or thien-3-yl; the stereoisomers and racemates thereof, and the pharmaceutically acceptable salts of compounds of formulae IA and IB.
<BR><BR>It has now surprisingly been found that compounds of the present invention are useful against malaria.  Every year, between 300 and 500 million people develop malaria.  Close to 3 million people die as a result of this disease, most of them
children and nearly all of them living in tropical Africa.  Fifty years ago, many people thought that malaria could be completely eradicated.  But over the past twenty years, malaria has been making a comeback.  For years, chloroquine has been the
standard treatment, but in some areas the malaria parasite is resistant to chloroquine and to cocktails of almost all the older antimalarials.  Around 40% of the world's population now live in areas where malaria is found.
<BR><BR>The compounds of the invention have the property that they are active not only against chloroquine-sensitive, but also against chloroquine-resistant malaria pathogens.  For this reason they are very well suited for the prophylaxis and treatment
of malaria, especially in cases where the malaria pathogens are resistant to chloroquine.
<BR><BR>Most of the above described .beta.-alkoxyacrylates and their salts are known compounds.  They are described in the following documents: EP 379 098; EP 299 694; WO 9007493; EP 278 595; EP 463 488; EP 370 629; EP 475 158; EP 474 042; EP 178 826; DE
3 519 280; EP 433 233; EP 460 575 and EP 254 426 as compounds with fungicidal activity for use in agriculture.
<BR><BR>The following compounds of formula IA5 are novel: ##STR16## wherein
<BR><BR>R.sup.1 is lower alkyl,
<BR><BR>X is N or CH,
<BR><BR>R.sup.4 is hydrogen or lower alkyl and
<BR><BR>A.sup.5 is phenyl which is unsubstituted or unsubstituted or substituted by one or more substituents selected from lower alkyl, lower alkoxy, NO.sub.2, halogen, cyano or CF.sub.3 ; pyridin-2-yl; pyridin-4-yl; quinolin-2-yl; quinolin-3-yl;
naphthyl; pyrrol-2-yl which is unsubstituted or substituted by lower alkyl; furan-2-yl, furan-3-yl; thien-2-yl; thien-3-yl which is unsubstituted or substituted by halogen and lower alkyl; thiazol-2-yl which is unsubstituted or substituted by C.sub.6
H.sub.4 Cl; thiazol-4-yl which is unsubstituted or substituted by phenyl; benzo[b]thiophen-2-yl which is unsubstituted or substituted by halogen; or benzo[b]thiophen-3-yl;
<BR><BR>as well as their pharmaceutically acceptable salts.
<BR><BR>Objects of the present invention are the use of the mentioned compounds of formulae IA and IB and their pharmaceutically acceptable salts thereof against chloroquine-sensitive and chloroquine resistant malaria pathogens, the use of these
compounds for making the corresponding medicaments medicaments containing these compounds and their salts as well as new compounds of formula IA5 per se.
<BR><BR>The following definitions of the terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
<BR><BR>As used herein, the term "lower alkyl" denotes a straight or branched-chain alkyl group containing from 1-4 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl and the like.
<BR><BR>The term "halogen" denotes chlorine, iodine, fluorine or bromine.
<BR><BR>The term "lower alkoxy" denotes an alkyl group, as defined earlier which is attached via an oxygen atom.  The term "cycloalkyl" denotes saturated cyclic hydrocarbon residues containing 3 to 6 carbon atoms.
<BR><BR>The present invention embraces all possible racemates and their optical antipodes.
<BR><BR>Preferred compounds of formula IA are especially those of formula IA5, ##STR17## in which R.sup.1 is methyl, X is CH, R.sup.4 is hydrogen and A.sup.5 is phenyl which is substituted by one or more substituents selected from CF.sub.3, bromine,
chlorine, methoxy, NO.sub.2 or lower alkyl; naphthyl; or thienyl.
<BR><BR>Compounds of formula IA2 ##STR18## in which R.sup.1 is methyl, X is CH, R.sup.2 is hydrogen or lower alkyl and A.sup.2 is phenyl which is substituted by CF.sub.3, chloro, fluoro, methyl, t-butyl or SCH.sub.3 are also preferred.
<BR><BR>Another group of preferred compounds is the following: ##STR19## in which R.sup.1 is methyl, X is CH, Y is O or S and A.sup.1 is phenyl which is unsubstituted or substituted by methyl, isopropyl, t-butyl, bromo, chloro, CF.sub.3 or methoxy;
naphthalenyl; or thiadiazolyl which is unsubstituted or substituted by thiomethyl or propynylthiocyclopropyl.
<BR><BR>The following intermediates which are used in the process for preparation of compounds of formulae IA4 show also a pharmaceutical activity against malaria pathogens: ##STR20##
<BR><BR>The compounds of formulae IA and IB can be prepared as described in the documents cited above.
<BR><BR>In addition, compounds of formulas IA1-IA9 and IB 1-IB5, can be prepared in accordance with Schemes 1-14.  ##STR21## wherein the substituents have the significances described above.  ##STR22## wherein the substituents have the significances
described above.  ##STR23## wherein the substituents have the significances described above.  ##STR24## wherein the substituents have the significances described above.  ##STR25## wherein the substituents have the significances described above. 
##STR26## wherein the substituents have the significances described above.  ##STR27## wherein the substituents have the significances described above.  ##STR28## wherein the substituents have the significances described above.  ##STR29## wherein the
substituents have the significances described above.  ##STR30## wherein the substituents have the significances described above.  ##STR31## wherein the substituents have the significances described above.  ##STR32## wherein the substituents have the
significances described above.  ##STR33## wherein the substituents have the significances described above.  ##STR34## wherein the substituents have the significances described above.
<BR><BR>The novel compounds of formula IA5 can be prepared in accordance with Scheme 5 and by Examples 164-206.
<BR><BR>As mentioned earlier, the .beta.-alkoxyacrylates of formulae IA and IB in accordance with the invention and their pharmaceutically usable salts have valuable pharmaceutical properties.
<BR><BR>In particular, they have a very good activity against malaria pathogens.  Their activity is equally good against chloroquine-resistant strains of the pathogen as against chloroquine-sensitive strains.  Accordingly, the present compounds can also
be used for the prophylaxis and cure of malaria even in those cases where the pathogen does not respond to chloroquine.
<BR><BR>In the following table are described the tested compounds:
<BR><BR>__________________________________________________________________________ IA1  ##STR35##  R.sup.1  X Y A.sup.1 Expl.No.  __________________________________________________________________________ CH.sub.3  --CH  S  ##STR36## 1  CH.sub.3  CH S 
##STR37## 2  CH.sub.3  --CH  S  ##STR38## 3  CH.sub.3  --CH  S  ##STR39## 4  CH.sub.3  --CH  S  ##STR40## 5  CH.sub.3  --CH  S  ##STR41## 6  CH.sub.3  CH S  ##STR42## 7  CH.sub.3  --CH  S  ##STR43## 8  CH.sub.3  CH S  ##STR44## 9  CH.sub.3  CH S 
##STR45## 10  CH.sub.3  CH S  ##STR46## 11  CH.sub.3  CH S  ##STR47## 12  CH.sub.3  CH S  ##STR48## 13  CH.sub.3  CH S  ##STR49## 14  CH.sub.3  CH S  ##STR50## 15  CH.sub.3  CH S  ##STR51## 16  CH.sub.3  CH S  ##STR52## 17  CH.sub.3  CH S  ##STR53## 18 
CH.sub.3  CH S  ##STR54## 19  CH.sub.3  CH S  ##STR55## 20  CH.sub.3  CH S  ##STR56## 21  CH.sub.3  CH S  ##STR57## 22  CH.sub.3  CH S  ##STR58## 23  CH.sub.3  CH S  ##STR59## 24  CH.sub.3  CH S  ##STR60## 25  CH.sub.3  CH S  ##STR61## 26  CH.sub.3  CH O ##STR62## 27  CH.sub.3  CH O  ##STR63## 28  CH.sub.3  CH O  ##STR64## 29  CH.sub.3  CH O  ##STR65## 30  CH.sub.3  CH O  ##STR66## 31  CH.sub.3  CH O  ##STR67## 32  CH.sub.3  CH O  ##STR68## 33  CH.sub.3  CH O  ##STR69## 34  CH.sub.3  CH O  ##STR70## 35 
__________________________________________________________________________
<BR><BR>Preferred compounds are also those of formula IA1 wherein R.sup.1 is methyl, X is CH, Y is S or O, A.sup.1 is phenyl which is substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, CF.sub.3, NO.sub.2, NH.sub.2,
phenoxy, or CF.sub.3 -phenoxy.  Such compounds can be prepared according to the procedure set in example 1 of EP 278595, like the following specific compounds:
<BR><BR>(E)-2-[2-(2-Bromo-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester;
<BR><BR>(E)-3-methoxy-2-[2-(4-phenoxy-phenoxymethyl)-phenyl]-acrylic acid methyl ester;
<BR><BR>(E)-3-methoxy-2-[2-[4-(4-trifluoromethyl-phenoxy)-phenoxymethyl]-phenyl]-ac rylic acid methyl ester;
<BR><BR>(E)-3-methoxy-2-[2-(4-methoxy-2-nitro-phenoxymethyl)-phenyl]-acrylic acid methyl ester;
<BR><BR>(E)-2-[2-(2,4-dibromo-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester;
<BR><BR>(E)-2-[2-(2-chloro-4-methyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester;
<BR><BR>(E)-2-[2-(2-chloro-4-trifluoromethyl-phenoxymethyl)-phenyl]-3-methoxy-acryl ic acid methyl ester;
<BR><BR>(E)-3-methoxy-2-(2-pentafluorophenyloxymethyl-phenyl)-acrylic acid methyl ester;
<BR><BR>(E)-2-[2-(2,4-dichloro-phenylsulfanylmethyl) -phenyl]-3-methoxy-acrylic acid methyl ester;
<BR><BR>(E)-2-[2-(2-amino-4-trifluoromethyl-phenylsulfanylmethyl)-phenyl]-3-methoxy -acrylic acid methyl ester;
<BR><BR>(E)-2-[2-(2-amino-4-methoxy-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester; and
<BR><BR>(E)-2-[2 -(4-tert-butyl-2 -chloro-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester.
<BR><BR>______________________________________ IA2  ##STR71##  Expl.  R.sup.1  X R.sup.2 A.sup.2 No.  ______________________________________ CH.sub.3  CH --C(O)OCH.sub.3  ##STR72## 36  CH.sub.3  CH CF.sub.3  ##STR73## 37  CH.sub.3  CH CH.sub.3  ##STR74##
38  CH.sub.3  CH --(CH.sub.2).sub.2 CH.sub.3  ##STR75## 39  CH.sub.3  CH  ##STR76##  ##STR77## 40  CH.sub.3  CH  ##STR78##  ##STR79## 41  CH.sub.3  CH --CH.sub.2 OCH.sub.3  ##STR80## 42  CH.sub.3  CH CH.sub.3  ##STR81## 43  CH.sub.3  CH CH.sub.3 
##STR82## 44  CH.sub.3  CH H  ##STR83## 45  CH.sub.3  CH CH.sub.2 CH.sub.3  ##STR84## 46  CH.sub.3  CH CH.sub.3  ##STR85## 47  CH.sub.3  CH CH.sub.3  ##STR86## 48  CH.sub.3  CH CH.sub.3 CH.sub.3  ##STR87## 49  CH.sub.3  CH CH.sub.2 CH.sub.3  ##STR88## 50 CH.sub.3  CH CH.sub.2 CH.sub.3  ##STR89## 51  CH.sub.3  CH CH.sub.3  ##STR90## 52  CH.sub.3  CH CH.sub.3  ##STR91## 53  CH.sub.3  CH CH.sub.3  ##STR92## 54  CH.sub.3  CH CH.sub.3  ##STR93## 55  CH.sub.3  CH CH.sub.3  ##STR94## 56  CH.sub.3  CH CH.sub.2
CH.sub.3  ##STR95## 57  CH.sub.3  CH CH.sub.2 CH.sub.3  ##STR96## 58  CH.sub.3  CH CH.sub.2 CH.sub.3  ##STR97## 59  CH.sub.3  CH CH.sub.2 SCH.sub.3  ##STR98## 60  CH.sub.3  CH CH.sub.3  ##STR99## 61  CH.sub.3  CH H  ##STR100## 62  CH.sub.3  CH H 
##STR101## 63  CH.sub.3  CH H  ##STR102## 64  CH.sub.3  CH H  ##STR103## 65  CH.sub.3  CH H  ##STR104## 66  CH.sub.3
<BR><BR> CH CH.sub.2 CH.sub.3  ##STR105## 67  CH.sub.3  CH H  ##STR106## 68  CH.sub.3  CH CH.sub.3  ##STR107## 69  CH.sub.3  CH CH.sub.3  ##STR108## 70  CH.sub.3  CH H  ##STR109## 71  CH.sub.3  CH H  ##STR110## 72  CH.sub.3  CH CH.sub.3  ##STR111## 73 
CH.sub.3  CH CH.sub.3  ##STR112## 74  CH.sub.3  CH CH.sub.3  ##STR113## 75  CH.sub.3  CH CH.sub.3  ##STR114## 76  CH.sub.3  CH CH.sub.3  ##STR115## 77  CH.sub.3  CH CH.sub.3  ##STR116## 78  CH.sub.3  CH CH.sub.3  ##STR117## 79  CH.sub.3  CH CH.sub.3 
##STR118## 80  CH.sub.3  CH CH.sub.3  ##STR119## 81  CH.sub.3  CH CH.sub.3  ##STR120## 82  CH.sub.3  CH CH.sub.3  ##STR121## 83  CH.sub.3  CH CH.sub.3  ##STR122## 84  CH.sub.3  CH CH.sub.3  ##STR123## 85  CH.sub.3  CH CH.sub.3  ##STR124## 86  CH.sub.3 
CH H  ##STR125## 87  CH.sub.3  CH CH.sub.3  ##STR126## 88  CH.sub.3  CH CH.sub.3  ##STR127## 89  CH.sub.3  CH CH.sub.2 CH.sub.3  ##STR128## 90  CH.sub.3  CH (CH.sub.2).sub.2 CH.sub.3  ##STR129## 91  CH.sub.3  CH  ##STR130##  ##STR131## 92  CH.sub.3  CH
CH.sub.3  ##STR132## 93  CH.sub.3  CH CH.sub.3  ##STR133## 94  CH.sub.3  CH H  ##STR134## 95  CH.sub.3  CH CF.sub.3  ##STR135## 96  CH.sub.3  CH CH.sub.3  ##STR136## 97  CH.sub.3  CH H  ##STR137## 98  CH.sub.3  CH H  ##STR138## 99  CH.sub.3  CH H 
##STR139## 100  CH.sub.3  CH CH.sub.3  ##STR140## 101  CH.sub.3  CH H  ##STR141## 102  CH.sub.3  CH H  ##STR142## 103  CH.sub.3  CH CH.sub.3  ##STR143## 104  CH.sub.3  CH CH.sub.3  ##STR144## 105  CH.sub.3  CH CH.sub.3  ##STR145## 106  CH.sub.3  CH
CH.sub.3  ##STR146## 107  CH.sub.3  CH CH.sub.3  ##STR147## 108  CH.sub.3  CH CH.sub.3  ##STR148## 109  CH.sub.3  N CH.sub.3  ##STR149## 110  CH.sub.3  N CH.sub.3  ##STR150## 111  CH.sub.3  N CF.sub.3  ##STR151## 112  CH.sub.3  N CH.sub.3  ##STR152## 113 CH.sub.3  N CH.sub.3  ##STR153## 114  CH.sub.3  N CH.sub.3  ##STR154## 115  CH.sub.3  CH CH.sub.3  ##STR155## 116  CH.sub.3  CH CH.sub.3  ##STR156## 117  ______________________________________
<BR><BR>______________________________________ IA3  ##STR157##  R.sup.1  X R.sup.3  W A.sup.3 Expl.No.  ______________________________________ CH.sub.3  CH H.sub.2  S  ##STR158## 118  CH.sub.3  CH H.sub.2  S  ##STR159## 119  CH.sub.3  CH H.sub.2  S 
##STR160## 120  CH.sub.3  CH H.sub.2  S  ##STR161## 121  CH.sub.3  CH H.sub.2  O  ##STR162## 122  CH.sub.3  CH H.sub.2  NH  ##STR163## 123  CH.sub.3  CH H.sub.2  NH  ##STR164## 124  CH.sub.3  CH CH.sub.3  CH.sub.2  ##STR165## 125 
______________________________________
<BR><BR>Preferred compounds are also those of formula IA3 wherein R.sup.1 is methyl, X is CH--, R.sup.3 is H.sup.2, W is S, O, A.sup.3 is phenyl which is substituted by one or more substituents selected from halogen, CF.sub.3, lower alkyl or is
5-acetoxy-6-acetoxymethyl-5,6-dihydro-2H-pyran.  Such compounds can be prepared according to the procedure set out in example 118, like the following additional compounds:
<BR><BR>(E)-2-[2-[(E)-3-(5-Acetoxy-6-acetoxymethyl-5,6-dihydxo-2H-pyran-2-yloxy)-pr openyl]-phenyl]-3-methoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(E)-3-(2-chloro-phenylsulfanyl)-propenyl]-phenyl]-3-methoxy-acryl ic acid methyl ester,
<BR><BR>(E)-2-[2-[(E)-3-(2-chloro-4-methyl-phenoxy)-propenyl]-phenyl]-3-methoxy-acr ylic acid methyl ester, and
<BR><BR>(E)-2-[2-[(E)-3-(2-chloro-4-trifluoromethyl-phenoxy)-propenyl]-phenyl]-3-me thoxy-acrylic acid methyl ester.
<BR><BR>______________________________________ ##STR166##  R.sup.1  X A.sup.4 Expl. No.  ______________________________________ CH.sub.3  CH  ##STR167## E/E 126  CH.sub.3  CH  ##STR168## E/Z 127  CH.sub.3  CH  ##STR169## E/Z 128  CH.sub.3  CH  ##STR170##
E/E 129  CH.sub.3  CH  ##STR171## 130  CH.sub.3  CH  ##STR172## E/E 131  CH.sub.3  CH  ##STR173## E/Z 132  CH.sub.3  CH  ##STR174## 133  CH.sub.3  CH  ##STR175## 134  CH.sub.3  CH  ##STR176## 135  CH.sub.3  CH  ##STR177## 136  CH.sub.3  CH  ##STR178##
137  CH.sub.3
<BR><BR> CH  ##STR179## 138  CH.sub.3  CH  ##STR180## 139  CH.sub.3  CH  ##STR181## 140  CH.sub.3  CH  ##STR182## 141  CH.sub.3  CH  ##STR183## 142  CH.sub.3  CH  ##STR184## 143  CH.sub.3  CH  ##STR185## 144  CH.sub.3  CH  ##STR186## 145  CH.sub.3  CH 
##STR187## E/E 146  CH.sub.3  CH  ##STR188## E/Z 147  CH.sub.3  CH  ##STR189## 148  CH.sub.3  CH  ##STR190## 149  CH.sub.3  CH  ##STR191## 150  CH.sub.3  CH  ##STR192## 151  CH.sub.3  CH  ##STR193## 152  CH.sub.3  CH  ##STR194## 153  CH.sub.3  CH 
##STR195## 154  CH.sub.3  CH  ##STR196## 155  CH.sub.3  CH  ##STR197## 156  CH.sub.3  CH  ##STR198## 157  CH.sub.3  CH  ##STR199## 158  CH.sub.3  CH  ##STR200## 159  CH.sub.3  CH  ##STR201## 160  CH.sub.3  CH  ##STR202## 161  CH.sub.3  CH  ##STR203## 162 CH.sub.3  CH  ##STR204## 163  ______________________________________
<BR><BR>Preferred compounds are also those of formula IA4 wherein R.sup.1 is methyl, X is CH, and A.sup.4 is phenyl which is substituted by one or more substituents selected from halogen, lower alkoxy, NO.sub.2, styryl-phenyl, or (2-CF.sub.3 --, or
Cl-phenyl)-furan-2-yl.  Such compounds can be prepared according to the procedure set in example 126 (EP-475158 A2 920318), like:
<BR><BR>(E)-3-Methoxy-2-[2-[(E)-2-[5-(2-trifluoromethyl-phenyl)-furan-2-yl]-vinyl]- phenyl]-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(E)-2-(2-chloro-3,4-dimethoxy-6-nitro-phenyl)-vinyl]-phenyl]-3-me thoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(E)-2-[5-(2-chloro-phenyl)-furan-2-yl]-vinyl]-phenyl]-3-methoxy-a crylic acid methyl ester and
<BR><BR>(E)-3-methoxy-2-[2-[(E)-2-[(E)-4-styryl-phenyl]-vinyl]-phenyl]-acrylic acid methyl ester.
<BR><BR>______________________________________ ##STR205##  R.sup.1  R.sup.4  A.sup.5 X Expl. No.  ______________________________________ CH.sub.3  H  ##STR206## CH 164  CH.sub.3  H  ##STR207## CH 164  CH.sub.3  H  ##STR208## CH 165  CH.sub.3  H 
##STR209## CH 166  CH.sub.3  H  ##STR210## CH 167  CH.sub.3  H  ##STR211## CH 168  CH.sub.3  H  ##STR212## CH 169  CH.sub.3  H  ##STR213## CH 170  CH.sub.3  H  ##STR214## CH 171  CH.sub.3  H  ##STR215## CH 172  CH.sub.3  H  ##STR216## CH 173  CH.sub.3  H ##STR217## CH 174  CH.sub.3  H  ##STR218## CH 175  CH.sub.3  H  ##STR219## CH 176  CH.sub.3  H  ##STR220## CH 177  CH.sub.3  H  ##STR221## CH 178  CH.sub.3  H  ##STR222## CH 179  CH.sub.3  H  ##STR223## CH 180  CH.sub.3  H  ##STR224## CH 181  CH.sub.3  H ##STR225## CH 182  CH.sub.3  H  ##STR226## CH 183  CH.sub.3  H  ##STR227## CH 184  CH.sub.3  H  ##STR228## CH 185  CH.sub.3  H  ##STR229## CH 186  CH.sub.3  H  ##STR230## CH 187  CH.sub.3  H  ##STR231## CH 188  CH.sub.3  H  ##STR232## CH 189  CH.sub.3  H ##STR233## CH 190  CH.sub.3  H  ##STR234## CH 191  CH.sub.3  H  ##STR235## CH 192  CH.sub.3  H  ##STR236## CH 193  CH.sub.3  H  ##STR237## CH 194  CH.sub.3  H  ##STR238## CH 195  CH.sub.3  H  ##STR239## CH 196  CH.sub.3  H  ##STR240## CH 197  CH.sub.3  H ##STR241## CH 198  CH.sub.3  H  ##STR242## CH 199  CH.sub.3  H  ##STR243## CH 201  CH.sub.3  H  ##STR244## CH 202  CH.sub.3  H  ##STR245## CH 203  CH.sub.3  H  ##STR246## CH 204  CH.sub.3  H  ##STR247## CH 205  CH.sub.3  H  ##STR248## CH 206 
______________________________________
<BR><BR>Preferred compounds are also those of formula IA5 wherein R.sup.1 is methyl, X is CH, R.sup.4 is H and A.sup.5 is phenyl, which is substituted by one or more substituents selected from lower alkyl, lower alkoxy, NO.sub.2, halogen, cyano, or
CF.sub.3.  Such compounds can be prepared according to the procedure set out in example 164, like:
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2-Chloro-3,4-dimethoxy-phenyl)-buta-1,3-dienyl]-phenyl ]-3-methoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2-bromo-4,5-dimethoxy-phenyl)-buta-1,3-dienyl]-phenyl] -3-methoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2-cyano-phenyl)-buta-1,3-dienyl]-phenyl]-3-methoxy-acr ylic acid methyl ester,
<BR><BR>(E)-3-methoxy-2-[2-[(1E,3E)-4-(3-methoxy-2-nitro-phenyl)-buta-1,3-dienyl]-p henyl]-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(4-fluoro-2-trifluoromethyl-phenyl)-buta-1,3-dienyl]-ph enyl]-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(4-fluoro-2-trifluoromethyl-phenyl)-buta-1,3-dienyl]-ph enyl]-3-methoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(4-tert-butyl-phenyl)-buta-1,3-dienyl]-phenyl]-3-methox y-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2-chloro-4-fluoro-phenyl)-buta-1,3-dienyl]-phenyl]-3-m ethoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2,4-difluoro-phenyl)-buta-1,3-dienyl]-phenyl]-3-methox y-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2-chloro-4-methyl-phenyl)-buta-1,3-dienyl]-phenyl]-3-m ethoxy-acrylic acid methyl ester,
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2,4-dimethyl-phenyl)-buta-1,3-dienyl]-phenyl]-3-methox y-acrylic acid methyl ester and
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2-fluoro-4-trifluoromethyl-phenyl)-buta-1,3-dienyl]-ph enyl]-3-methoxy-acrylic acid methyl ester.
<BR><BR>______________________________________ IA6  ##STR249##  R.sup.1  X A.sup.6 Expl.No.  ______________________________________ CH.sub.3  N  ##STR250## 207  CH.sub.3  N  ##STR251## 208  ______________________________________ IA7  ##STR252##  R.sup.1 
X A.sup.7 Expl.No.  ______________________________________ CH.sub.3  N  ##STR253## 209  ______________________________________ IA8  ##STR254##  R.sup.1  X A.sup.8 Expl.No  ______________________________________ CH.sub.3  CH  ##STR255## 210  CH.sub.3  CH 
##STR256## 211  CH.sub.3  CH  ##STR257## 212  CH.sub.3  CH  ##STR258## 213  CH.sub.3  CH  ##STR259## 214  CH.sub.3  N  ##STR260## 215  CH.sub.3  N  ##STR261## 216  ______________________________________ IA9  ##STR262##  R.sup.1  X A.sup.9 Expl.No 
______________________________________ CH.sub.3  B  ##STR263## 217  IB1  ##STR264##  R.sup.1  V B.sup.1 X Expl.No  ______________________________________ CH.sub.3  --O--  ##STR265## CH 218  CH.sub.3  --O--  ##STR266## CH 219  CH.sub.3  --N(CH.sub.3)-- 
##STR267## CH 220  CH.sub.3  --N(CH.sub.3)--  ##STR268## CH 221  CH.sub.3  --N(CH.sub.3)--  ##STR269## CH 222  CH.sub.3  --N(CH.sub.3)--  ##STR270## CH 223  CH.sub.3  --S--  ##STR271## CH 224  ______________________________________ IB2  ##STR272## 
R.sup.1 B.sup.2 X m Expl.No.  ______________________________________ CH.sub.3  ##STR273## CH 1 225  CH.sub.3  ##STR274## CH 0 226  CH.sub.3  ##STR275## CH 0 227  CH.sub.3  ##STR276## CH 1 228  CH.sub.3  ##STR277## CH 1 229  CH.sub.3  ##STR278## CH 1 230 
CH.sub.3  ##STR279## CH 1 231  CH.sub.3  ##STR280## CH 1 232  CH.sub.3  ##STR281## CH 1 233  CH.sub.3  ##STR282## CH 0 234  CH.sub.3  ##STR283## CH 1 235  ______________________________________ IB3  ##STR284##  R.sup.1  B.sup.3 X Expl.No. 
______________________________________ CH.sub.3  ##STR285## CH 236  ______________________________________ IB4  ##STR286##  R.sup.1  R.sup.5 B.sup.4 X Expl.No  ______________________________________ CH.sub.3  ##STR287##  ##STR288## CH 237  CH.sub.3 
CH.sub.3  ##STR289## CH 238  CH.sub.3  CH.sub.3  ##STR290## CH 239  CH.sub.3  H  ##STR291## CH 240  ______________________________________ IB5  ##STR292##  R.sup.1  B.sup.5 X Expl.No.  ______________________________________ CH.sub.3  ##STR293## CH 241 
CH.sub.3  ##STR294## CH 242  CH.sub.3  ##STR295## CH 243  ______________________________________ IB  ##STR296##  R.sup.1  Z R.sup.6 R.sup.7  R.sup.8  Expl.No  ______________________________________ CH.sub.3  ##STR297## H H H 244  CH.sub.3  CH.sub.3 H H
CH.sub.3  245  CH.sub.3  Br H H H 246  CH.sub.3  H --OCH.sub.3  H H 247  CH.sub.3  H H --OCH.sub.3  H 248  CH.sub.3  Cl H H H 249  CH.sub.3  H H H CH.sub.3  250  ______________________________________
<BR><BR>The activity of the compounds against not only chloroquine-resistant, but also chloroquine-sensitive malaria pathogens shows itself in a strong, in vitro measurable growth inhibition of various strains of the human-pathogenic Plasmodium
falciparum, as set forth in Table 1 hereinafter.  The ratio of the growth inhibition of a strain which is especially resistant to chloroquine and of a strain which is sensitive to chloroquine gives as the "resistance index" a measurement for the absence
or presence of a cross-resistance with chloroquine.  Since, for all novel compounds the resistance index lies between 0.7 and 2.5, they inhibit the growth of sensitive as well as resistant strains of the malaria pathogen equally effectively.  They are
accordingly also suitable for the prophylaxis of a malaria disease and also for the treatment of a malaria disease even when chloroquine is ineffective.  The good activity against malaria pathogens is also shown in animal experiments.  The effective
doses measured after oral and subcutaneous administration to mice infected with malaria pathogens are shown in Table 2 hereinafter.
<BR><BR>Test method for the determination of the activity against Plasmodium falciparum in vitro
<BR><BR>The preparations are tested on intraerythrocytary stages of Plasmodium falciparum from asynchronous cultures according to the method of Desjardin et al. (Desjardins, R. E. et al: Quantitative assessment of antimalarial activity in vitro by a
semiautomated microdilution technique.  Antimicrob.  Agents Chemother.  16, 710-718, (1979)).
<BR><BR>The culture medium consists of RPMI 1640 with the addition of 25 mM HEPES, 25 mM NaHCO.sub.3, 100 .mu.g/ml neomycin and 10% human serum (A.sup.+).  Human-A.sup.+ erythrocytes are used as the Plasmodium falciparum host cells.  The parasites are
maintained at 37.degree.  C. in an atmosphere of 3% O.sub.2, 4% CO.sub.2, 93% N.sub.2 and 95% relative humidity.
<BR><BR>In order to determine the activity, the preparations are dissolved in DMSO, pre-diluted in the culture medium to a suitable starting concentration and subsequently titrated-out on to microtitre plates in the 2nd stage over 6-7 steps.  After the
addition of the parasite culture (0.7% parasitemia in 2.5% erythrocyte suspension) the test plates are incubated under the conditions given above for 72 h. The parasite growth in the different preparation concentrations is determined using [G-.sup.3
H]-hypoxanthin incorporation compared to untreated control cultures on the same test plates.  The 50% growth inhibition (IC.sub.50) is calculated according to logit regression analysis from the resulting dosage-activity curve.
<BR><BR>The preparations are tested on at least one chloroquine-resistant and one chloroquine-sensitive Plasmodium falciparum strain.  Additional sensitive and resistant strains are included for further characterization.
<BR><BR>Test method for the determination of the activity against Plasmodium berghei in vivo
<BR><BR>The preparations are tested on mice infected with malaria pathogens (Plasmodium berghei).  Male albino mice (IBM:MORO(SPF), FUELLINSDORF) weighing about 25 g are used as the test animals.  They are kept in climatized rooms at 21-22.degree.  C. in
groups of 5 animals per cage.  They receive ad libitum a diet feed with a low PABA content (NAFAG FUTTER" No. 9009 PAB-45, PABA content 45 mg/kg) and drinking water.  On the first day of the test (D0) the test animals are infected with Plasmodium berghei
(strain ANKA).  For this there is used heparinized blood of a donor mouse with about 30% parasitemia, which is diluted with physiological saline such that it contains 10.sup.8 parasitized erythrocytes per ml.  0.2 ml of this suspension is injected
intravenously (i.v.) into the mice to be treated and into the control mice.  In untreated control animals the parasitemia normally reaches 30-40% on the third day after the infection (D+3) and the test animals die between days +5 and +7.
<BR><BR>The substances to be tested are dissolved or suspended in distilled water or in a mixture of 7% Tween 80, 3% alcohol (96%) and water.  Usually, 0.25 ml of this solution or suspension is administered once subcutaneously and perorally to groups of
5 test animals.  Treatment is effected 24 hours after the infection.  10 control animals are treated in the same manner with solvent or suspension medium per test.
<BR><BR>All substances are tested in a first test in a single dosage of 100 or 10 mg/kg.  Only those substances which in this test (10 mg/kg) have shown a parasitaemia reduction of more than 90% are used for the titration.  Suitable dilutions of the test
substance can be used to obtain an accurate titration of the activity.
<BR><BR>48 hours after the treatment (D+3) blood smears are prepared from all animals using blood from tail veins and are stained with giemsa.  The
<BR><BR> average erythrocyte infection rate (parasitemiea in %) in the control groups as well as in the groups which have been treated with the test compounds is determined by counting under a microscope.  The difference in the average values of the
infection rates of control group (100%) and treated groups is calculated and expressed as a percentage reduction (GI%).  The ED.sub.50 or ED.sub.90 is determined mathematically by means of the JMP programme (nonlinear fit).  The ED.sub.50 (ED.sub.90) in
mg/kg is that dose which after single administration reduces the average erythrocyte infection rate by 50% (90%) in comparison to the control group.
<BR><BR> TABLE 1  ______________________________________ Values measured in vitro (IC.sub.50 values in .mu.g/ml) for the  grouth inhibition of the human-pathogenic Plasmodium falciparum  strain NF54 as an example of a chloroquine-sensitive strain and of
the  human-pathogenic Plasmodium flaciparum K1 as an example of a  chloroquine-resistant strain.  in vitro  strain NF 54  strain K1  Formula Example No. IC.sub.50 IC.sub.50 72 h  ______________________________________ IA1 11 1.17 4.9  IA1 28 17.7 19.1 
IA2 105 0.21 1.01  IA2 110 20 65.8  IA2 111 1.6 4.3  IA3 120 1.75 2.51  IA4 126 1.2 3.3  IA4 136 1.04 2.9  IA5 185 0.06 0.15  IA5 199 0.06 0.13  IA5 203 0.07 0.28  IA5 206 0.4 1.4  IA6 207 10.8 25.8  IA7 209 3.21 5.7  IA8 210 0.85 1.35  IA8 211 0.33 1.34 IA9 217 23.7 60.8  IB1 222 22, 6 64.3  1B4 238 17.5 40.9  IB5 241 1.4 7.4  IB5 243 6.7 22.6  IB 244 147.3 419.2  IB 250 184.4 550.3  IB2 233 29.5 67.3  IB3 236 44.2 174.7  III 251 64.9 111  ______________________________________
<BR><BR> TABLE 2  ______________________________________ Activity measured in vivo against Plasmodium berghei in mice in  percentage reduction of the parasitemia after a perorally (po) or  subcutaneously (sc) administered dose of 100 (10) mg/kg of test 
substance,  ED.sub.50 is the effective administered dose of test substance  in vivo  Formula Example No. po act. % sc act. %  ______________________________________ IA1 11 80 tox  IA3 120 46 91  IA4 126 79 76  IA4 136 40 tox  IA5 185 99.0 (10 mg/kg) 
99.95  IA5 199 100 (10 mg/kg)  99.97  IA5 203 76 (10 mg/kg)  90  IA5 206 46 44  IA8 210 82 99  IA8 211 59 (10 mg/kg)  92  III 251 40 74  ______________________________________
<BR><BR>The compounds of formula IA or IB and the pharmaceutically acceptable acid addition salts of the compounds of formula IA or IB can be used as medicaments, e.g. in the form of pharmaceutical preparations.  The pharmaceutical preparations can be
administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.  The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally,
e.g. in the form of injection solutions, or nasally.
<BR><BR>The compounds of formula IA or IB and the pharmaceutically acceptable acid addition salts of the compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.  Suitable carriers for soft gelatine capsules are, for
example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like.  Depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatine capsules.  Suitable carriers for the production of
solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like.  Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
<BR><BR>The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. 
They can also contain still other therapeutically valuable substances.
<BR><BR>Medicaments containing a compound of formula IA or IB or a pharmaceutically acceptable acid addition salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for making them which comprises
bringing one or more compounds of formula IA or IB and/or pharmaceutically acceptable acid addition salts thereof into a galenical administration form together with one or more therapeutically inert carriers.
<BR><BR>In accordance with the invention compounds of formula IA or IB as well as their pharmaceutically acceptable acid addition salts can be used for the treatment or prevention of malaria and, respectively, for the production of corresponding
medicaments.  The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.  In the case of oral administration the dosage lies in a range of about 10 mg to about 2.5 g per day of a compound
of general formula IA or IB or the corresponding amount of a pharmaceutically acceptable acid addition salt thereof, although the upper limit can also be exceeded when this is found to be indicated.
<BR><BR>In the following Examples, which illustrate the present invention but are not intended to limit its scope in any manner, all temperatures are given in degrees Celsius.  The 250 MHz-.sup.1 H-NMR spectra were measured at room temperature; chemical
shifts .delta.  (ppm) relative to .delta.  (TMS)=0.0 ppm.
<BR><BR>The novel compounds of formula IA5 can be prepared as described below.  All temperature are given in .degree.  C. <BR><BR>EXAMPLE 164
<BR><BR>(E)-2-[2-(1E,3E)-4-[4,5-Dimethoxy-2-nitro-phenyl)-buta-1,3-dienyl]-phenyl]- 3-methoxy-acrylic acid methyl ester
<BR><BR>a) At room temperature, NaOCH.sub.3 (335 mg, 6.19 mmol) was added to a solution of 1,3-dioxan-2-ylmethyltributylphosphoniumbromide (C. Spangler; R. McCoy, Synthetic communications, 18, 51, (1988)) (5.17 ml, 1 M in DMF, 5.71 mmol) and
4,5-dimethoxy-2-nitro-benzaldehyde (1.25 g, 4.76 mmol) in DMF (20 ml).  After heating the mixture at 50.degree.  for overnight, the mixture was poured over water, and extracted with ether, washed with brine and dried over MgSO.sub.4.  The solvent was
evaporated and the residue was dissolved in THF (100 ml) and treated with 2 N HCl (50 ml).  After stirring the mixture at room temperature for 2 h, the THF was evaporated, and the yellow solid was filtered, and suspended in ether/ethylacetate 4:1.  The
suspension stirred at room temperature for 1 h, filtered and washed with ether to afford (E)-3-(4,5-dimethoxy-2-nitro-phenyl)-propenal (624 mg, 55%) as a yellow solid, m.p.  103-105.degree..  IR (KBr): 1689, 1605 cm.sup.-1.  MS (EI): 237 (M).
<BR><BR>b) At 0.degree., NaH (40 mg, 0.954 mmol) was added to a solution of (E)-2-[2-(dimethoxy-phosphorylmethyl)-phenyl]-3-methoxy-acrylic acid methyl ester (EP-203606) (250 mg, 0.79 mmol) in THF (5 ml).  The mixture was stirred at room temperature for
30 min and treated with (E)-3-(4,5-dimethoxy-2-nitro-phenyl)-propenal (189 mg, 0.79 mmol) in CH.sub.2 Cl.sub.2 (2 ml).  After the mixture was stirred at room temperature for 3 h and refluxed for 1.5 h, the reaction mixture was cooled to room temperature
and treated with CH.sub.3 CO.sub.2 H (1 ml).  After stirring for 10 min at room temperature, the reaction mixture was extracted with ethylacetate, washed with NaHCO.sub.3 solution, brine, water, and dried over MgSO.sub.4.  Evaporation of the solvent and
chromatography (hexane/ethylacetate 1:1) gave (E)-2-[2-(1E,3E)-4-[4,5-dimethoxy-2-nitro-phenyl)-buta-1,3-dienyl]-phenyl] -3-methoxy-acrylic acid methyl ester (116 mg, 34%) as white solid, m.p.  198-200.degree..  IR (KBr): 1710, 1630 cm.sup.-1.  MS (EI):
425 (M).
<BR><BR>According to the procedure set forth in the preceding example, the following compounds were prepared:
<BR><BR>EXAMPLE 165
<BR><BR>(E)-2-[2-[(1E,3E)-4-(2,4-Dichloro-phenyl)-buta-1,3-dienyl]-phenyl]-3-methox y-acrylic acid methyl ester
<BR><BR>m.p.  143-145.degree.
<BR><BR>IR (KBr): 1707, 1629 cm.sup.-1, MS (EI): 388 (M)
<BR><BR>EXAMPLE 166
<BR><BR>Methyl (E and/or Z)-3-methoxy-2- [o-[(all-E)-4-(2-pyridyl)-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  106-108.degree.
<BR><BR>EXAMPLE 167
<BR><BR>Methyl (E and/or Z)-2-[o-[(all-E)-4-(2,3-dichloro-phenyl)-1,3-butadienyl]-phenyl]-3-methoxy acrylate
<BR><BR>m.p.  141-145.degree.
<BR><BR>EXAMPLE 168
<BR><BR>Methyl (E and/or Z)-2-[o-[(all -E)-4-(2,3-difluorophenyl)-1,3-butadienyl]-phenyl]-3-methoxyacrylate
<BR><BR>m.p.  142-144.degree.
<BR><BR>EXAMPLE 169
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E)-4-(2-quinolinyl)-1,3-butadienyl]phenyl]acrylate
<BR><BR>m.p.  137-138.degree.
<BR><BR>EXAMPLE 170
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E)-4-(1-naphthyl)-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  138-140.degree.
<BR><BR>EXAMPLE 171
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E)-4-(1-methylpyrrol-2-yl)-1,3-butadienyl]phenyl]a crylate
<BR><BR>m.p.  139-142.degree.
<BR><BR>EXAMPLE 172
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E)-4-(4-pyridyl)-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  175-177.degree.
<BR><BR>EXAMPLE 173
<BR><BR>Methyl (E and/or Z)-2-[o-[(all-E)-4-(2-furyl)-1,3-butadienyl]phenyl]-3-methoxyacrylate
<BR><BR>m.p.  136-137.degree.
<BR><BR>EXAMPLE 174
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E)-4-(2-thienyl)-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  142-145.degree.
<BR><BR>EXAMPLE 175
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E and/or Z)-4-(3-thienyl)-1,3-butadienyl]phenyl]acrylate
<BR><BR>m.p.  194-195.degree.
<BR><BR>EXAMPLE 176
<BR><BR>Methyl (E and/or Z)-3-methoxy-2-[o-[(all-E)-4-(3-quinolinyl)-1,3-butadienyl]phenyl]-3-metho xyacrylate
<BR><BR>m.p.  173-175.degree.
<BR><BR>EXAMPLE 177
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(alpha,alpha, alpha-trifuoro-p-tolyl)-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  190-191.degree.
<BR><BR>EXAMPLE 178
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(p-fluorophenyl)-1,3-butadienyl]phenyl]-3-methoxyacryl ate
<BR><BR>m.p.  156-157.degree.
<BR><BR>EXAMPLE 179
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(o-ethoxyphenyl)-1,3-butadienyl]phenyl]-3-methoxyacryl ate
<BR><BR>m.p.  152-153.degree.
<BR><BR>EXAMPLE 180
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(2-chloro-6-fluorophenyl)-1,3-butadienyl]phenyl]-acryl ate
<BR><BR>m.p.  165.degree.
<BR><BR>EXAMPLE 181
<BR><BR>Methlyl (E)-3-methoxy-2-[o-[(all-E)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1,3-bu tadienyl]phenyl]acrylate
<BR><BR>m.p.  152-153.degree.
<BR><BR>EXAMPLE 182
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(3-furyl)-1,3-butadienyl]phenyl]-3-methoxyacrylate
<BR><BR>m.p.  174-175.degree.
<BR><BR>EXAMPLE 183
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-[2-(-p-chloro-phenyl)-4-thiazolyl]-1,3-butadienyl]-phe nyl]-3-methoxyacrylate
<BR><BR>m.p.  167-171.degree.
<BR><BR>EXAMPLE 184
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(o-chlorophenyl)-1,3-butadienyl]phenyl]acrylate
<BR><BR>m.p.  158-162.degree.
<BR><BR>EXAMPLE 185
<BR><BR>Methyl
<BR><BR> (E)-3-methoxy-2-[o-[(all-E)-4-(alpha,alpha,alpha-trifluoro-tolyl)-1,3-buta dienyl]-phenl]acrylate
<BR><BR>m.p.  148-149.degree.
<BR><BR>EXAMPLE 186
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(m-fluorophenyl)-1,3-butadienyl]phenyl]-3-methoxyacryl ate
<BR><BR>IR (KBr): 1705, 1628 cm.sup.-1, MS (EI): 338 (M)
<BR><BR>EXAMPLE 187
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(5-phenyl-4-thiazolyl)-1,3-butadienyl]-pheny l]acrylate
<BR><BR>m.p.  167.degree.
<BR><BR>EXAMPLE 188
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(5-bromo-2-thienyl)-1,3-butadienyl]phenyl]-3-methoxyac rylate
<BR><BR>m.p.  160-161.degree.
<BR><BR>EXAMPLE 189
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(-p-methoxyphenyl)-1,3-butadienyl]-phenyl]ac rylate
<BR><BR>m.p.  164-166.degree.
<BR><BR>EXAMPLE 190
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-[3-methoxybenzo[b]thiophen-2-yl]-1,3-butadie nyl]phenyl]acrylate
<BR><BR>m.p.  202-203.degree.
<BR><BR>EXAMPLE 191
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-3-(2 -thiazolyl)-1,3 -butadienyl]phenyl]-acrylate
<BR><BR>m.p.  131-133.degree.
<BR><BR>EXAMPLE 192
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(5-methyl-2-thienyl)-1,3-butadienyl]-phenyl] acrylate
<BR><BR>m.p.  131-133.degree.
<BR><BR>EXAMPLE 193
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(3-methyl-2-thienyl)-1,3-butadienyl]-phenyl] acrylate
<BR><BR>m.p.  168.degree.
<BR><BR>EXAMPLE 194
<BR><BR>Methyl (E)-3-methoxy-2-[o-[4-(2-naphthyl)-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  172.degree.
<BR><BR>EXAMPLE 195
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-benzo[b]thiophen-2-yl-1,3-butadienyl]phenyl]-3-methoxy -acrylate
<BR><BR>m.p.  223-225.degree.
<BR><BR>EXAMPLE 196
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-benzo[b]thiophen-3-yl-1,3-butadienyl]phenyl]-3-methoxy -acrylate
<BR><BR>m.p.  157.degree.
<BR><BR>EXAMPLE 197
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-phenyl-1,3-butadienyl]-phenyl]acrylate
<BR><BR>m.p.  165-167.degree.
<BR><BR>EXAMPLE 198
<BR><BR>(E)- or (Z)-2-[2-[4-(3,5-bis-trifluoromethyl-phenyl)-buta-1,3-dienyl]phenyl]-3-met hoxy-acrylic acid methyl ester
<BR><BR>IR (KBr): 1703, 1630 cm.sup.-1
<BR><BR>MS (EI): 456 (M)
<BR><BR>EXAMPLE 199
<BR><BR>(E)- or (Z)-2-[2-[4-(2,4-bis-trifluoromethyl-phenyl)-buta-1,3-dienyl]phenyl]-3-met hoxy-acrylic acid methyl ester
<BR><BR>m.p.  176-177.degree.
<BR><BR>IR (KBr): 1703, 1630 cm.sup.-1
<BR><BR>MS (EI): 456 (M)
<BR><BR>EXAMPLE 200
<BR><BR>Methyl-2-[o-[(all-E)-4-(m-bromophenyl)-1,3-butadienyl]phenyl]-3-methoxy-acr ylic
<BR><BR>IR (KBr): 1701, 1626 cm.sup.-1
<BR><BR>MS (EI): 399 (M)
<BR><BR>EXAMPLE 201
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(p-chlorophenyl)-1,3-butadienyl]-phenyl]-3-methoxyacry late
<BR><BR>m.p.  209.degree.
<BR><BR>EXAMPLE 202
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(m-chlorophenyl)-1,3-butadienyl]phenyl]-3-methoxyacryl ate
<BR><BR>m.p.  121-122.degree.
<BR><BR>EXAMPLE 203
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(o-bromophenyl)-1,3-butadienyl]phenyl]-3-methoxyacryla te
<BR><BR>m.p.  150-151.degree.
<BR><BR>EXAMPLE 204
<BR><BR>Methyl (E)-3-methoxy-2-[o-[(all-E)-4-(3,4,5-trimethoxyphenyl)-1,3-butadienyl]phen yl]acrylate
<BR><BR>m.p.  98-109.degree.
<BR><BR>EXAMPLE 205
<BR><BR>Methyl (E)-2-[o-[(all-E)-4-(p-tert-butylphenyl)-3-methyl-1,3-butadienyl]-phenyl]3 -methoxyacrylate
<BR><BR>IR (KBr): 1709, 1632 cm.sup.-1
<BR><BR>MS (EI): 390 (M)
<BR><BR>EXAMPLE 206
<BR><BR>(Z)- or (E)-Methoxyimino-[2-[(1E,2E)-4-(2-trifluoromethylphenyl)-buta-1,3-dienyl]- phenyl]-acetic acid methyl ester
<BR><BR>a) At 24.degree., Bu.sub.3 SnH (0.56 ml, 2.1 mmol) was added to a solution of (2-ethynyl-phenyl)-methoxyimino-acetic acid methyl ester (151 mg, 0.7 mmol) and AIBN (cat.) in toluene (0.5 ml).  After the mixture was stirred at 80.degree.  for 3.5
h, solvent was evaporated under reduced pressure and chromatography (hexane/ethylacetate 9:1) gave methoxyimino-[2-(E,Z)-(2-tributylstannanyl-vinyl)-phenyl]-acetic acid methyl ester (1:1 mixture) (155 mg, 44%) as a yellowish liquid.  IR (KBr): 1731, 1600
cm-.sup.1.  MS (EI): 508 (M).
<BR><BR>b) A solution of 1-(2,2-dibromo-vinyl)-2-trifluoromethyl-benzene (989 mg, 3 mmol), and Et).sub.2 POH (0.75 ml, 6 mmol) in Et.sub.3 N (0.83 ml, 6 mmol) was stirred at 5.degree.  for 4 h. Hexane was added, and stirred for further 10 min. The
mixture was extracted with hexane, washed with brine and dried over Na.sub.2 SO.sub.4.  Evaporation of the solvent and chromatography (hexane) gave 1-(2-bromo-vinyl)-2-trifluoromethyl-benzene (674 mg, 90%) as a colorless liquid.  IR (KBr): 1600, 940
cm.sup.-1.  MS (EI): 251 (M).
<BR><BR>c) At 24.degree., Pd[PPh.sub.3 ].sub.4 (21 mg, 0.02 mmol) was added to a solution of 1-(1-bromo-vinyl)-2-trifluoromethyl-benzene (151 mg, 0.6 mmol) and methoxy-imino-[2-(E,Z)-(2-tributylstannanyl-vinyl)-phenyl]-acetic acid methyl ester (304 mg,
0.6 mmol) in toluene (5 ml).  The mixture was stirred at 110.degree.  for 5 h, cooled to room temperature, extracted with toluene, washed with brine, and dried over Na.sub.2 SO.sub.4.  Evaporation of the solvent and chromatography (hexane/ethylacetate
3:2) gave (Z)- or (E)-methoxyimino-[2-[(lE,2E)-4-(2-trifluoromethylphenyl)-buta-1,3-dienyl]- phenyl]-acetic acid methyl ester (48 mg, 21%) as brown oil.  IR (KBr): 1734, 1610 cm.sup.-1.  MS (EI): 389 (M).
<BR><BR>EXAMPLE 251 (III)
<BR><BR>(E)-3-Methoxy-2-{(E)-2-[(R)- and (S)-3-(tetrahydro-pyran-2-yloxy}-propenyl]-phenyl}-acrylic acid methyl ester (active intermediate)
<BR><BR>At 24.degree., Pd[PPh.sub.3 ].sub.4 (58 mg, 0.05 mmol) was added to a solution of (E)-tributyl-[3-(R)- and (S)-(tetrahydro-pyran-2-yloxy)-propenyl]-stannane (2.2 g, 5.1 mmol) (E. J. Corey; J. W. Suggs, J. Org. Chem. 40, 2554, (1975)) and
(E)-2-(2-bromo-phenyl)-3-methoxy acid methyl ester (1.38 mg, 5.1 mmol) (EP 0307101 A2 890315) in toluene (20 ml).  The mixture was stirred at 110.degree.  for 2 days, cooled to room temperature, extracted with toluene, washed with brine, and dried over
Na.sub.2 SO.sub.4.  Evaporation of the solvent and chromatography (hexane/ethylacetate 9:1) gave (E)-3-methoxy-2-[(E)-2-[(R)- and (S)-3-(tetrahydro-pyran-2-yloxy)-propenyl]-phenyl]-acrylic acid methyl ester (884 mg, 52%) as a white solid, m.p. 
66-68.degree..  IR (Br): 1711, 1633 cm .sup.-1.  MS (EI): 216 (M-MeOH-Dihydropyrane).
<BR><BR>EXAMPLE 252 (IV)
<BR><BR>(E)-2-[2-(3-Hydroxy-propenyl)-phenyl]-3-methoxy-acrylic acid methyl ester (active intermediate)
<BR><BR>At 24.degree., toluene-4-sulfonic acid monohydrate (1.11 g, 0.4 mmol) was added to a solution of (E)-3-methoxy-2-[(E)-2-[(R)- and (S)-3-(tetrahydro-pyran-2-yloxy)-propenyl]-phenyl]-acrylic acid methyl ester (4.866 g, 14 mmol) in ethanol (70 ml). 
After the mixture was stirred for 6 h and neutralized with K.sub.2 CO.sub.3 solution, the solvent was evaporated and the crude was dissolved in ethylacetate, washed with brine, water, and dried over Na.sub.2 SO.sub.4.  Evaporation of the solvent gave
(E)-2-[2-(3-hydroxy-propenyl)-phenyl]-3-methoxy-acrylic acid methyl ester (3.4 g, 93%) as a white solid, m.p.  78-80.degree..  IR (YBr): 1683, 1619 cm.sup.-1.  MS (EI): 216 (M-MeOH).
<BR><BR>EXAMPLE A
<BR><BR>(E)-2-[2-(1E,3E)-4-[4,5-dimethoxy-2-nitro-phenyl)-buta-1,3-dienyl]-phenyl]- 3-methoxyacrylic acid methyl ester can be formulated as the active ingredient according to methods known per se to give pharmaceutical preparations of the following
composition:
<BR><BR>______________________________________ 1. 500 mg tablets  Active ingredient 500 mg  Powd. lactose 149 mg  Polyvinylpyrrolidone 15 mg  2. Dioctyl sodium sulphosuccinate  1 mg  Na carboxymethylstareh  30 mg  Magnesium stearate 5 mg  700 mg  2. 50
mg tablets  Active ingredient 50 mg  Powd. lactose 50 mg  Microcrystalline cellulose  82 mg  Na carboxymethylstarch  15 mg  200 mg  3. 100 mg capsules  Active ingredient 100.0 mg  Powd. lactose 104.7 mg  Corn starch 70.0 mg  Hydroxypropylmethylcellulose 
10.0 mg  Dioctyl sodium sulphosuccinate  0.3 mg  Talc 12.0 mg  Magnesium stearate 3.0 mg  300.0 mg  4. 500 mg suppositories  Active ingredient 500 mg  Suppository mass ad 2000 mg  5. 100 mg soft gelatine capsules  Active ingredient 100 mg  Medium chain
triglyceride  300 mg  400 mg  ______________________________________
<BR><BR><CENTER><b>* * * * *</b></CENTER>
<HR>
   <CENTER>
   <a href=http://pdfpiw.uspto.gov/.piw?Docid=06084120&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D35%2526p%3D1%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526S1%3D(chloroquine.TI.%252BOR%252Bchloroquine.ABTX.)%2526OS%3D%252B((ttl%2Fchloroquine%252Bor%252Babst%2Fchloroquine))%2526RS%3D(TTL%2Fchloroquine%252BOR%252BABST%2Fchloroquine)&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page><img src="/netaicon/PTO/image.gif" alt="[Image]" border="0" valign="middle"></A>
   <TABLE>
   <TR><TD align="center"><A href="https://certifiedcopycenter.uspto.gov/other/patft/view.html?backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D35%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(chloroquine.TI.%252BOR%252Bchloroquine.ABTX.)%26OS%3D%252B((ttl%2Fchloroquine%252Bor%252Babst%2Fchloroquine))&backLabel1=Back%20to%20Document%3A%206084120"><IMG border="0" src="/netaicon/PTO/cart.gif" border="0" valign="m
iddle" alt="[View Shopping Cart]"></A>
   <A href="https://certifiedcopycenter.uspto.gov/other/patft/order.html?docNumber=6084120&backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D35%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(chloroquine.TI.%252BOR%252Bchloroquine.ABTX.)%26OS%3D%252B((ttl%2Fchloroquine%252Bor%252Babst%2Fchloroquine))&backLabel1=Back%20to%20Document%3A%206084120">
   <IMG border="0" src="/netaicon/PTO/order.gif" valign="middle" alt="[Add to Shopping Cart]"></A>
   </TD></TR>
   <TR><TD align="center">
     <A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=35&p=1&f=S&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&Query=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/hitlist.gif border=0 ALT=[HIT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=35&p=2&f=S&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&Query=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextlist.gif border=0 ALT=[NEXT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=34&p=1&f=G&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&OS=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/prevdoc.gif border=0 ALT=[PREV_DOC]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=36&p=1&f=G&l=50&d=PTXT&S1=(chloroquine.TI.+OR+chloroquine.ABTX.)&OS=+((ttl/chloroquine+or+abst/chloroquine))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextdoc.gif border=0 ALT=[NEXT_DOC]></A>

   <A href="#top"><IMG valign="middle" src="/netaicon/PTO/top.gif" border="0" alt="[Top]"></A>
   </TD></TR>
   </TABLE>
   <A name="bottom"></A>
   <A href="/netahtml/PTO/index.html"><IMG src="/netaicon/PTO/home.gif" alt="[Home]" border="0" valign="middle"></A>
   <A href="/netahtml/PTO/search-bool.html"><IMG src="/netaicon/PTO/boolean.gif" alt="[Boolean Search]" border="0" valign="middle"></A>
   <A href="/netahtml/PTO/search-adv.htm"><IMG border="0" src="/netaicon/PTO/manual.gif" alt="[Manual Search]" valign="middle"></A>
   <A href="/netahtml/PTO/srchnum.htm"><IMG src="/netaicon/PTO/number.gif" alt="[Number Search]" border="0" valign="middle"></A>
   <A href="/netahtml/PTO/help/help.htm"><IMG border="0" src="/netaicon/PTO/help.gif" alt="[Help]" valign="middle"></A>
   </CENTER>
</BODY>
</HTML>